Dokument: Lipoprotection in cardiovascular diseases
| Titel: | Lipoprotection in cardiovascular diseases | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=67941 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20241210-114010-5 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Benkhoff, Marcel [Autor] Polzin, Amin [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Heart failure, Acute myocardial infarction, Coronary artery disease, Lipoprotection, Sphingosine-1-phosphate | |||||||
| Beschreibung: | Cardioprotection is a well-established term in the scientific world. It describes the protection of various mediators on the cardiovascular system. These protective effects can also be provided by certain lipids. Since lipids are a very specific and clearly definable class of substances, we define the term lipoprotection as lipid-mediated cardioprotection. In this review, we highlight high-density lipoprotein (HDL), sphingosine-1-phosphate (S1P) and omega-3 polyunsaturated fatty acids (n-3 PUFA) as the most important lipoprotective mediators and show their beneficial impact on coronary artery disease (CAD), acute myocardial infarction (AMI) and heart failure (HF). | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Benkhoff, M., & Polzin, A. (2024). Lipoprotection in cardiovascular diseases. Pharmacology & Therapeutics, 264, Article 108747. https://doi.org/10.1016/j.pharmthera.2024.108747 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 10.12.2024 | |||||||
| Dateien geändert am: | 10.12.2024 |
